Prospective Study
Copyright ©The Author(s) 2015.
World J Gastroenterol. Aug 7, 2015; 21(29): 8935-8942
Published online Aug 7, 2015. doi: 10.3748/wjg.v21.i29.8935
Table 2 Baseline variables according to treatment response
VariableAll subjects
HCV genotype-1
HCV genotype-3
R(n = 130)NR(n = 22)R(n = 77)NR(n = 17)R(n = 51)NR(n = 5)
Age (yr)40.9 ± 9.4a47.7 ± 11.541.7 ± 9.047.9 ± 11.940.0 ± 10.146.8 ± 8.9
HCV RNA (× 105 IU/mL)35.6 ± 55a60.1 ± 99.537.9 ± 48.670.1 ± 111.632.4 ± 64.926.3 ± 16.8
Liver fibrosis stage2.2 ± 1.53.0 ± 1.72.3 ± 1.53.0 ± 1.81.8 ± 1.33.0 ± 0.0
ALT (IU/L)71.9 ± 57.7100.9 ± 108.774.2 ± 63.977.9 ± 63.770.1 ± 47.9198.7 ± 203.6
AST (IU/L)44.5 ± 26.471.2 ± 66.844.9 ± 28.758.5 ± 47.644.4 ± 23.3125.2 ± 113.5
BMI (kg/m2)26.9 ± 4.025.8 ± 3.427.2 ± 3.5a25.1 ± 3.026.2 ± 4.629.5 ± 3.7